Biotech and pharmaceutical interest in psoriasis treatments continues. Here are a couple items just from the last few days.
Manhattan Pharmaceuticals, on the heels of announcing that their obesity drug candidate had failed in Phase 2a trials (an important reminder of the risks of new treatment development), was quick to reiterate its hopes in its
READ THE FULL POST
|
|||||||||||||
|
